In 2018, I joined the Prostate Cancer Glycosylation Group as a PDRA researching how glycan reprogamming of prostate cancer cells affects their cellular phenotypes. Whilst here I also worked to generate the preliminary data for a patented diagnostic test for prostate cancer based on our understanding of prostate cancer associated glycans.

In 2020 I was awarded the Prostate Cancer UK Travelling Prize fellowship. This is a four year project, in which I will be trying to understand how glycan reprograming of prostate cancer cells promotes immune evasion, and using this understanding to develop novel glyco-immune combination therapies for the treatment of prostate cancer. As part of this fellowship I plan to travel to Stanford University to join the lab of Prof Sharon Pitteri based at the Canary Centre for the Early Detection of Cancer. 

I sit on the Newcastle University Biosciences Institute Equality, Diversity and Inclusion Steering Committee. 

Research Positions

2020-2024 Prostate Cancer UK Travelling Prize Fellow. Biosciences Institute, Newcastle University.

2018-2020 Research Assistant/Associate. Institute of Genetic Medicine, Newcastle University.

2015-2019 PhD Student. Institute of Cellular Medicine, Newcastle University. 

2014-2015 Masters Student. North West Cancer Research Centre, University of Liverpool. 

Funding

2020 - 'Glycans as novel targets to boost immunotherapy in prostate cancer'. Prostate Cancer UK Travelling Prize Fellowship. £299,443. 

2020 - 'Glycoscore - A non-invasive test for prostate cancer.' Northern Accelerator CCF award. £49,655. (Co-investigator, Jennifer Munkley Principle Investigator). 

2019 - 'Using glycan sugars to improve the diagnosis of prostate cancer.' JGW Patterson Foundation. £49,909. (Co-investigator, Jennifer Munkley Principle Investigator).

2019 - 'GlycoScore: Validation of a non-invasive diagnostic test to distinguish between benign and aggressive prostate cancer. MRC Confidence in Concepts. £81,146. (Co-investigator, Jennifer Munkley Principle Investigator). 

2019 - Travel support to visit a collaborator at Stanford University. Wellcome ISSF (Broadening our Horizons). £1800. 

2019 - Support to attend a glycosylation workshop. Wellcome ISSF (Broadening our Horizons). £1205.

2018 - EASL NAFLD Summit Young Investigator Award. £650.

2017 - 'Expert training in lipidomics at Cambridge University.' MRC Doctoral Training Supplement. £6000. 

Presentations

2019 - Prostate Cancer UK Making Progress Happen Event (London, UK). Selected poster.

2019 - Cancer Research UK Early Detection of Cancer Conference (Stanford, USA). Selected poster and oral presentation.

2019 - Newcastle University FMS PostDoc Symposium (Newcastle, UK). Selected oral presentation.

2019 - Glycosylation Workshop (San Sebastian, Spain). Selected poster. 

2018 - European Association for Study of the Liver NAFLD Summit (Geneva, Switzerland). Selected poster. 

Project Students

I regularly supervise Undergraduate and MRes project students in the lab. 

PhD Supervision

Kayla Bastian 2019 - 2022

Rebecca Garnham 2020-2023

Emily Archer-Goode 2020-2023

• Hall Z, Chiarugi D, Charidemou E, Leslie J, Scott E, Pelligrinet L, Allison M, Mocciaro G, Anstee QM, Evan GI, Hoare M, VidalPuig A, Oakley F, Vacca M, Griffin JL. Lipid remodelling in hepatocyte proliferation and hepatocellular carcinoma . Hepatology 2020, epub ahead of print.
• Scott E, Elliott DJ, Munkley J. Tumour associated glycans: A route to boost immunotherapy?. Clinica Chimica Acta 2020, 502, 167-173.
• Munkley J, Li L, Krishnan SRG, Hysenaj G, Scott E, Dalgliesh C, Oo HZ, Maia TM, Cheung K, Ehrmann I, Livermore KE, Zielinska H, Thompson O, Knight B, McCullagh P, McGrath J, Crundwell M, Harries LW, Daugaard M, Cockell S, Barbosa-Morais NL, Oltean S, Elliott DJ. Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. eLife 2019, 8, e47678.
• Scott E, Munkley J. Glycans as Biomarkers in Prostate Cancer. International Journal of Molecular Sciences 2019, 20(6), 1389.
• Garnham R, Scott E, Livermore KE, Munkley J. ST6GAL1: A key player in cancer (Review). Oncology Letters 2019, 18(2), 983-989.
• Munkley J, Scott E. Targeting Aberrant Sialylation to Treat Cancer. Medicines 2019, 6(4), 102.
• Scott EJ, Anstee QM. The genetics of alcoholic liver disease and non-alcoholic steatohepatitis. Clinical Medicine 2018, 18(Suppl. 2), s54-s59.
• Luukkonen PK, Zhou Y, Nidhina Haridas PA, Dwivedi OP, Hyotylainen T, Ali A, Juuti A, Leivonen M, Tukiainen T, Ahonen L, Scott E, Palmer JM, Arola J, Orho-Melander M, Vikman P, Anstee QM, Olkkonen VM, Oresic M, Groop L, Yki-Jarvinen H. Impaired hepatic lipid synthesis from polyunsaturated fatty acids in TM6SF2 E167K variant carriers with NAFLD. Journal of Hepatology 2017, 67(1), 128-136.
• Govaere O, Petz M, Wouters J, Vandewynckel Y-P, Scott EJ, Topal B, Nevens F, Verslype C, Anstee QM, Van Vlierberghe H, Mikulits W, Roskams T. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene 2017, 36, 6605-6616.